Drug
ACE1831
ACE1831 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Recruiting1
Completed1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 12 (66.7%)
N/A1 (33.3%)
Trials by Status
recruiting133%
completed133%
not_yet_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
completedphase_1
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
NCT05653271
recruitingphase_1
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
NCT07061938
not_yet_recruitingnot_applicable
ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）
NCT07314567
Clinical Trials (3)
Showing 3 of 3 trials
NCT05653271Phase 1
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
NCT07061938Phase 1
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
NCT07314567Not Applicable
ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3